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nvestigations and pre-clinical and clinical safety studies, may help
o make informed decisions in clinical practice.
Methods: Pre-clinical toxicology and clinical safety assess-
ents, both within the context of controlled clinical trials and
ost-marketing surveillance, are conducted for all licensed vac-
ines. In addition pre-clinical adjuvant MoA studies provide
dditional information regarding the safety proﬁle of novel adju-
anted vaccines. Our discussion will focus on the added support
hat MoA studies bring to the safety evaluation of adjuvanted vac-
ines. As an example of MoA and safety data we will use the results
f studies with the AS04-adjuvanted L1/16&18 HPV vaccine.
Results: The preclinical toxicology package of the AS04-
djuvanted L1/16&18 HPV vaccine has not shown treatment-
elated toxicologyﬁndings other than local injection site inﬂamma-
ion. MoA data showed that AS04 induced a transient and localised
ctivation of innate cells at the injection site and in the local drain-
ng lymph nodes, with no systemic impact or direct effect on T
ells and B-cellls. Clinical safety evaluation and follow-up in a trial
etting have shown no clinically relevant differences compared
ith control groups other than reactogenicity, mostly at local level,
onsistent with ﬁndings from preclinical data and MoA studies.
inally, with more than 25 million doses distributed worldwide,
ost-licensure safety evaluations have shown adverse events con-
istent with what has been observed in the clinical development
rogram, with most commonly reported events being local site
eactions of short duration (2-3 days).
Conclusion:Regulatory authorities require rigorouspre-clinical
nd clinical safety data to determine the beneﬁt/risk proﬁle of new
accines. Post-licensure, a continuous pharmacovigilance system
s in place to further assess vaccine safety. Research studying the
echanism of action of an adjuvanted vaccine can help to further
nvestigate the vaccine’s safety proﬁle.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1008
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uberculin skin test andBCGscar in childrenvaccinatedatbirth:
study from Iran
. raﬁei tabatabaei1,∗, F. Shiva2, H. Mohebati3, H. Behbod3, A.
arimi1
Pediatric infectious Research disease, Tehran, Iran, Islamic Republic
f
Pediatric Infections Research Center, Shaheed Beheshti University of
edical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of
Pediatric Infectious Research Center, Shaheed Beheshti University,
ehran, IRAN, Tehran, Iran, Islamic Republic of
Background: The rates of positive tuberculin skin test reactions
nd BCG scarring after BCG vaccination vary between studies and
opulations. Tuberculin reactivity and BCG scarring may be related
o better child survival in low-income countries.
This studywasperformedtoassess the reaction to the tuberculin
kin test and the development of the BCG scar in a cohort of healthy
ewborns.
Methods: We performed the tuberculin test with Puriﬁed pro-
ein derivative (PPD) and the BCG scar in 794 infants 3months after
accination at birth in Arak, Iran.fectious Diseases 16S (2012) e158–e316
Results: Of all children 413 were female (52%). Response to
the tuberculin test was negative in 39%, doubtful in 55% and posi-
tive in 6%. In 96% of cases B.C.G scar was ≥3mm in diameter. The
average size of the reaction to PPD in those with a BCG scar was
greater than those without a scar in all the children in our study,
(p-value <0.001).
Conclusion: In the present study about 96% of infants had a
successful response to BCG vaccination while 4% did not develop a
scar. In some countries repeat vaccination is universal; in others it
is based on either tuberculin skin testing or the absence of a typical
scar. Since the absence of development of the scar does not always
signify a lack of response to the BCG, therefore it is better to do fur-
ther immunological tests to detect a reaction to the vaccine before
deciding to revaccinate these children.
http://dx.doi.org/10.1016/j.ijid.2012.05.1009
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lar responses ofmice immunizedwith Leishmania recombinant
GP63 protein
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1 Shiraz University of Medical Sciences-Clinical Microbiology Research
Center, Shiraz, Iran, Islamic Republic of
2 Shiraz University of Medical Sciences-Clinical Microbiology Research
center, Shiraz, Iran, Islamic Republic of
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Background: Propolis is a natural resinous hive product, col-
lected by honey bees from plants and mixes with their wax.
Regarding to its pharmacological activities and adjuvants prop-
erty in vaccine formulations, the effect of propolis extracts on
the humoral and cellular immune responses can be exploited for
the development of effective vaccines. This work evaluated the
adjuvant capacity of an ethanol extract of propolis associated to
recombinant GP63 Leishmania protein.
Methods: Brieﬂy, the propoliswas ground andmacerated for 10
days with an extract solution containing absolute ethanol. Then,
the solvent was evaporated and the resulting dried matter was
dissolved in PBS. 27 male BALB/c mice, allocated into four groups,
were inoculated subcutaneously with 0.1ml of 4 different vaccines
formulates at day 0, 7 and 30. Group 1 to 4 have been injected
with normal saline, 50g recombinant (r) GP63, 50g rGP63 plus
5mgpropolis, and 5mgpropolis, respectively. 30 days after the last
inoculation, splenic mononuclear cells were obtained from spleens
of treated mice by Ficol hypaque gradient and 107 isolated cells
were resuspended in 1ml media supplemented with 10% of bovine
fetal serum. The105 cells plated in a 96 well plate and treated with
rGP63. After 4 days, the supernatant was assayed for the content of
IL-4 and IFN- by ELISA methods.
Results: The level of the IL-4 in the Propolis plus rGP63
group was signiﬁcantly higher than the control and rGP63 groups
(P =0.002, P =0.001, respectively). Based on the level of IFN-, no
signiﬁcant differences were observed between propolis plus rGP63
and other treated group.
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Conclusion: It can be concluded that the adjuvant property
f propolis ethanol extract may be useful for the stimulation of
umoral immuneresponses invaccinedesign for infectiousdisease.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1010
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asopharyngeal colonization of Streptococcus pneumoniae in
lderly people, in Jakarta, Indonesia
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Background: Streptococcus pneumoniae (S. pneumoniae) is a
eading cause of bacterial pneumonia, meningitis, and sepsis
orldwide. Incidence of invasive pneumococcal disease varies sub-
tantially by age, genetic background, socioeconomic and immune
tatus, and geographical location. Currently, few data exist on
neumococcal colonization in Indonesia. We only identiﬁed one
neumococcal colonization study in healthy children in Indonesia
Lombok Island) in 2001. Moreover, no data are yet available on
neumococcal colonization in elderly people in Indonesia.
Methods: A cross-sectional study was performed to investigate
he nasopharyngeal colonization of S. pneumonia in elderly people
uring routine clinic visits in Jakarta, Indonesia. 155 nasopharyn-
eal swabs were collected in STGG medium and cultured on blood
gar plateswith gentamicin and thus screened for alpha-hemolysis
nd optochin sensitivity. Molecular identiﬁcation of S. pneumo-
iae was also done by detection of psaA and lytA genes and the
NA analysis of .RecA and 16 s rRNA genes. Capsular serotyping was
etermined by sequentialmultiplex PCR and antibiotic susceptibil-
ty test was performed by etest method.
Results: We found ten a-haemolytic gram-positive isolates,
owever only four isolates were optochin susceptible and posi-
ive result for PsaA and LytA genes detection with the colonization
revalence is 2.6%. The three serotypes found were 3, 6A/B, 15B/C
nd one non-typeable. All pneumococcal isolate are susceptible to
enicillin and vancomycin.
Conclusion: The prevalence of nasopharyngeal colonization
f S. pneumoniae is low in elderly people in Jakarta, Indonesia.
his research will be important for pneumococcal surveillance in
ndonesia and application of pneumococcal vaccine in the future.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1011fectious Diseases 16S (2012) e158–e316 e313
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Immunogenicity and safety of a primary series of a new fully
liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (HexaximTM)
co-administeredwithPrevenarTM andRotarixTM inhealthy chil-
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Background: Lot-to-lot consistency study assessing primary
series vaccination with a new, fully liquid, DTaP–IPV–Hep B–PRP-T
vaccine (HexaximTM - an AcXim family vaccine), incorporating the
newHansenulapolymorpha–derivedHepBantigen (SanoﬁPasteur),
co-administered with PrevenarTM and RotarixTM.
Methods: Phase III, randomized, observer-blind, two-centre
study. Subjects received Hexaxim (Group 1: N=1002 [3 lots-
pooled]) or Infanrix hexaTM (Group 2: N=338) at 2,4,6 months-
of-age, co-administered with Prevenar (PCV7: 2, 4, 6 months) and
Rotarix (2, 4months).HepBwasgivenat birth. Antibody concentra-
tions or titers were measured pre-(Hep B, D, PT, FHA) and 1 month
post-(all valences) primary series for Hexaxim and Infanrix hexa.
Equivalence of Hexaxim lots was tested. Non–inferiority analyses
were performed for Group 1 versus Group 2 for seroprotection (SP:
anti- Hep B, PRP, D, T, and polio 1/2/3) and vaccine response (VR:
anti-PTandFHA) rates.Anti-PCV7 (7months) andanti-rotavirus IgA
(5months)werealsoassessed. Safetyafter eachdosewascompared
descriptively.
Results: Equivalence was demonstrated for the Hexaxim lots,
so Group 1 data were pooled for non-inferiority testing (per pro-
tocol analysis set). For all SP and VR rates, Group 1-minus-Group 2
non-inferioritywasdemonstrated (lower95%CI bound for eachdif-
ferencewas greater than the pre-speciﬁed non–inferioritymargin).
Anti-Hep B GMCs were similar in Groups 1 and 2 (3013 and 2766
mIU/mL); anti-PRPwas higher in Group 1 (3.56 versus 2.24g/mL).
There were no clinically relevant differences in the immune
responses to Prevenar or Rotarix following co-administration with
Hexaximor Infanrix hexa. Reactogenicitywas similar in each group
and no vaccine–related SAEs were reported.
Table 1: SP or VR (95% CI)
Group 1 Group 2
Anti-Hep B ≥10 mlU/mL 99.7 (99.1;99.9) 100(98.8;100)
Anti-PRP ≥ 0 15 ug/mL 94.6 (93.0;96.0) 95.9(93.1;97.8)
Anti-Diphtheria ≥ 0.01 IU/mL 100(99.6;100) 100(98.8;100)
Anti-Tetanus ≥ 0.01 IU/mL 100 (99.6;100) 100(98.8;100)
Anti-Polio 1 ≥8 (1/dil) 100 (99.6;100) 100(98.8;100)
Anti-Polio 2 ≥8 (1/dil) 100 (99.6;100) 100(98.8;100)
Anti-Polio 3 ≥8 (1/dil) 100(99.6;100) 99.7(98.2;100)
Anti-PT (EU/mL) 97.5 (96.3;98.4) 98.4 (96.3;99.5)
Anti-FHA (EU/mL) 99.8(99.2;100) 99.4 (97.7;99.9)
Conclusion: The new DTaP-IPV-Hep B-PRP-T vaccine is
immunogenic and safe following co-administration with Prevenar
and Rotarix, and similar to the licensed comparator.
http://dx.doi.org/10.1016/j.ijid.2012.05.1012
